Thursday 22 June 2017
The overall aim of the Stratified Medicine Initiative is the discovery and understanding of clinically important disease subtypes. Whether described as stratified, precision or personalised medicine, the research will provide new insights into disease mechanisms, that will enable better tailoring of existing treatments, and pave the way for the development of new treatments, diagnostics and care pathways.
Through this Initiative we currently support thirteen consortia, in disease areas of high industry interest and/or scientific potential. Together the supported consortia have attracted over forty small, medium and large companies from across the UK and internationally and are partnered with thirty-four universities. Each consortium is a scientific discovery engine with a finely characterised patient population at its heart contributing to a deeper understanding of disease process as well as trialling new and existing treatments in stratified groups for real patient benefit.
Scope of the call
This call aims to support new consortia to address disease areas where there is a strong case for scientific advancement and major unmet clinical need.
Up to £15m to fund consortia up to 5 years in duration will be available. There will be an opportunity for the MRC to leverage additional co-funding from potential funding partners, including Arthritis Research UK (ARUK), British Hearth Foundation (BHF), and Cancer Research UK (CRUK) for appropriate studies.
Who can apply?
This call is for successful outline applicants only.
Full proposals will be sent out for international peer review and then assessed by the Expert Review Panel. Full stage applicants will be invited to interview at the meeting on 2nd and 3rd November 2017 at MRC Head Office, One Kemble Street. Full details will follow in due course. Please note that this Panel will make the final funding decisions. The MRC also reserves the right to include an additional trial stage before the full meeting.